NCT00090545View on ClinicalTrials.gov

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 1, 2004

Primary Completion Date

September 1, 2007

Study Completion Date

April 1, 2009

Conditions
Prostate Cancer
Interventions
DRUG

BAY 43-9006

400 mg BAY 43-9006 orally twice daily in 28 day cycles.

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00090545 - A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | Biotech Hunter | Biotech Hunter